Thelansis’s “Rosacea Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Rosacea is a chronic inflammatory skin disorder involving neurovascular dysregulation, innate immune activation, barrier dysfunction, and, in some phenotypes, Demodex-associated inflammation. It commonly presents with persistent centrofacial erythema, flushing, telangiectasia, papules and pustules, with ocular and phymatous involvement in some patients. Management is phenotype-directed and includes photoprotection, topical ivermectin, metronidazole or azelaic acid, and brimonidine or oxymetazoline for persistent erythema. Low-dose doxycycline is used for inflammatory lesions, while lasers or surgery may address selected features. Minocycline ER (Emrosi) was FDA-approved in 2024 for inflammatory lesions in adults. Despite effective therapies, rosacea often requires long-term maintenance and can relapse. Development continues to explore anti-inflammatory, neurovascular, barrier, and microbiome-related mechanisms, with priorities including durable control and personalized care approaches.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Rosacea – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Rosacea – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.